OPRM1 and dysentery: Exploring the mechanism by which different components perform the same effects is a new way to develop drugs in the future; for example, 4-terpineol and beta-sitosterol can act on the two targets of the 5-hydroxytryptamine receptor 3A and the mu-type opioid receptor, respectively, and provide corresponding therapeutic effects on diarrhea and dysentery.